Polyvinyl Alcohol (PVA) for Wound Dressings (Medical Films)

Cast polyvinyl alcohol films destined for transparent wound dressings are manufactured via a controlled solution deposition process that starts with fully hydrolyzed PVA resin, typically grade 1799 (degree of polymerization ~1700, hydrolysis ≥99.0 mol%), dissolved in deionized water at 90–95 °C under mechanical stirring at 200–300 rpm for 2–3 hours to achieve a 10–15 wt% homogeneous aqueous dope. The solution is subsequently degassed in a vacuum chamber at −0.095 MPa for 30 minutes to eliminate entrapped microbubbles that would otherwise form pin-hole defects in the as-cast film. Glycerol is added as a plasticizer at 5–10 phr relative to dry PVA weight to reduce film brittleness and maintain conformability at low ambient humidity; insufficient glycerol loading (<3 phr) leads to edge curling and cracking during slitting, while excess amounts (>b>12 phr) cause tackiness and dimensional instability under EN 13726-3 moisture vapour transmission rate testing. The casting solution is fed through a slot-die coater with a lip gap set between 250 µm and 500 µm onto a polyethylene terephthalate release liner moving at 0.5–2.0 m/min. Drying is executed in a three-zone tunnel where air temperature ramps from 40 °C to 80 °C and relative humidity is maintained below 30% to prevent premature skinning; at RH > 60%, the film surface absorbs moisture rapidly and becomes tacky, necessitating pre-drying of the incoming release liner and enclosure of the casting area in a dehumidified cleanroom environment. Post-drying, the film passes through an inline annealing station at 120 °C for 15 minutes to increase crystallinity and reduce water sensitivity while preserving optical clarity. A chemical crosslinking step using glutaraldehyde at 0.1–0.3 wt% relative to PVA, catalysed by hydrochloric acid at pH 2–3, is optionally incorporated to tune gel fraction and swelling; residual aldehyde is subsequently leached by multiple immersion baths with water at 40 °C for 24 hours until spectrophotometric analysis confirms glutaraldehyde content below 5 µg/g, as required by ISO 10993-12 extraction limits. The final film is laminated with a low-tack acrylic adhesive and die-cut into individual dressing sheets or supplied in roll form. Compliance with EN 13726-1 fluid handling capacity, ASTM F2100-11 barrier properties, and ISO 10993-5 (cytotoxicity) and ISO 10993-10 (irritation and sensitisation) is mandatory for regulatory submission. The resulting transparent dressing allows wound bed inspection without removal and is typically employed as a secondary cover film over hydrogels or alginates for low-exuding partial-thickness wounds.

Can PVA Cryogels Replace Lyophilized Collagen in Temporary Skin Substitutes?

Physical crosslinking of polyvinyl alcohol through iterative freeze-thaw cycling yields a non-immunogenic, high-water-content hydrogel sheet that directly competes with animal-derived collagen dressings for donor site coverage and superficial burns. A grade with extremely high hydrolysis (≥99.2 mol%) and molecular weight (e.g., PVA 2099, DP ~2000) is dissolved at 8–12 wt% in water, poured into flat stainless-steel or PTFE-coated aluminium moulds to a depth of 2–4 mm, and subjected to 3–5 cycles of freezing at −20 °C for 8–12 hours followed by thawing at 25 °C for 4–6 hours. During freezing, ice crystal growth expels PVA chains into concentrated domains where polymer crystallization nucleates and forms physical junction zones; the cumulative crystallinity after three cycles reaches 8–12% as measured by differential scanning calorimetry per ASTM D3418, and climbs to 15–18% after five cycles. This progressive densification of the network raises tensile strength from approximately 0.2 MPa to 0.8 MPa (tested per ASTM D882 on swollen samples) but simultaneously reduces elongation at break below 100%, creating a narrow processing window where both mechanical integrity and pliability must be balanced. The absence of chemical crosslinkers eliminates post-production washing steps and toxicological risks related to residual aldehydes or initiators, which is a critical advantage for chronic wound and paediatric applications under ISO 10993-11 systemic toxicity evaluation. However, batch-to-batch variability in crystallinity due to freezer temperature gradients—even a ±2 °C deviation during the freezing ramp—can cause a measurable shift in gel fraction, making precise thermal profiling and in-process sampling essential. A comparative summary of crosslinking approaches is given in the following table.

Comparative Performance of PVA Hydrogel Crosslinking Methods for Wound Dressing Film

Crosslinking Method	Gel Fraction (%)(ASTM D2765 extractables test)	Equilibrium Swelling Ratio(gravimetric, phosphate-buffered saline)	Tensile Strength (MPa)(ASTM D882)	Processing Limitation
Freeze-thaw 3 cycles	45–60	8.0–12.0	0.2–0.4	Long cycle time; crystallinity sensitive to cooling rate
Freeze-thaw 5 cycles	65–80	5.0–8.0	0.6–1.0	Reduced elongation; potential edge shrinkage
Glutaraldehyde 0.2 wt%	85–95	3.5–6.0	1.2–2.5	Requires exhaustive aldehyde removal; pH-dependent reaction rate
Gamma irradiation 25 kGy	70–85	4.0–7.0	0.8–1.8	Radiolytic chain scission reduces molecular weight; dose mapping critical

The finished cryogel sheet is packaged in hydrated form between impermeable films and sterilised by gamma radiation at 25–40 kGy in accordance with ISO 11137-1. Terminal sterilisation dose must be established by bioburden method; overdosing beyond 40 kGy can induce radiolytic degradation that manifests as a sticky surface and measurable loss of crystallinity. The product is indicated as a temporary epidermal substitute for split-thickness skin graft donor sites, where its high moisture vapour transmission rate (MVTR > 2000 g/m²/24h per EN 13726-2) prevents maceration while the dressing resists microbial penetration (ASTM F1671). Regulatory compliance relies on ISO 10993-4 (haemocompatibility), ISO 10993-6 (local tissue reaction), and ISO 10993-11 (systemic toxicity), supported by a risk management file under ISO 14971.Micromolding of polyvinyl alcohol into dissolving microneedle arrays for transdermal drug delivery exploits the polymer’s water solubility and biocompatibility, with low-molecular-weight partially hydrolyzed grades such as PVA 0588 (hydrolysis 87–89 mol%, DP ~500) preferred because their faster dissolution kinetics in skin interstitial fluid (~pH 7.4, 37 °C) enable payload release within 10–30 minutes after insertion. The aqueous dope is prepared by dissolving PVA at 15–25 wt% along with the active pharmaceutical ingredient (e.g., insulin at 2–5% w/w relative to polymer) and a stabiliser such as sucrose or trehalose at 5–10% w/w to protect the drug during drying and storage. Microfabrication employs a polydimethylsiloxane (PDMS) mould replicated from a precision-machined master, typically featuring conical or pyramidal cavities with height 500–800 µm and base diameter 200–300 µm. The PVA solution is dispensed onto the mould and forced into the cavities under vacuum (−0.09 MPa for 10 minutes) to eliminate entrapped air that would otherwise truncate needle tips. After scraping off excess solution with a PTFE blade, the mould is dried in a convection oven at 30–35 °C for 12–24 hours; higher temperatures accelerate polymer crystallite formation and reduce dissolution rate, thereby extending release time beyond the target window. A backing layer of higher-molecular-weight PVA (1799, 20 wt%) or PVP is then cast over the dried needles and allowed to dry, creating a handleable patch with sufficient mechanical strength to penetrate the stratum corneum without bending failure—a failure that occurs when tip radius exceeds 20 µm or when needle water content drops below 5% leading to brittle fracture during insertion. The patch is demoulded and die-cut into individual units, then vacuum-packed with desiccant; moisture ingress above 10% RH during storage plasticises the matrix and reduces penetration efficiency to below 80% in ex vivo skin models. Biocompatibility assessment follows ISO 10993-10 for skin irritation and delayed-type hypersensitivity, and ISO 10993-12 for sample preparation; dissolution by-products are compliant with USP <87> cytotoxicity criteria. The finished transdermal microneedle patch is commercialised as a minimally invasive alternative for delivery of macromolecules such as vaccines, insulin, or lidocaine.

Iodophor-PVA Complexation Kinetics and Antimicrobial Release Profiles

Formation of a polyvinyl alcohol-iodine complex creates a reservoir-type antimicrobial dressing wherein molecular iodine is continuously released to maintain bactericidal activity against Gram-positive and Gram-negative organisms over several days. A completely hydrolysed, high-molecular-weight PVA (grade 1799) is dissolved at 10 wt% in purified water, and an iodine-potassium iodide solution (I₂/KI molar ratio 1:2, equivalent to 1–3% available iodine on dry PVA basis) is blended in under subdued light at 25 °C. UV-Vis spectrophotometry of the polymer-iodine complex reveals characteristic absorbance maxima at 360 nm and 600 nm, attributed to I₃⁻ bound within the PVA helical structure; incomplete complexation, indicated by residual free iodine absorbance at 460 nm, results in rapid initial burst release exceeding 200 µg/cm² within the first hour, which risks local cytotoxicity above the ISO 10993-5 threshold. The homogenised solution is cast onto a polyester release film using a knife-over-roll coater with a gap of 300–500 µm and dried at 50 °C in a dark enclosure to prevent photolytic decomposition. Post-drying, the film is conditioned at 40% RH and 23 °C for 48 hours to equilibrate moisture content, as variations above ±3% moisture alter iodine elution kinetics in subsequent dissolution testing per USP <71>. Terminal sterilisation is accomplished by ethylene oxide gas, because gamma irradiation induces rapid iodine release and discoloration; residual ethylene oxide levels are verified below 4 mg per device per ISO 10993-7. The antimicrobial activity is validated according to ASTM E2149-20 (shake flask method) and must demonstrate a ≥4 log reduction of Staphylococcus aureus and Pseudomonas aeruginosa within 24 hours. Physical performance is assessed via EN 13726-1 free swell absorptive capacity (≥150% of dry weight) and moisture vapour transmission rate (1000–1800 g/m²/24h) to ensure exudate handling without maceration. The iodophor-PVA dressing is supplied as translucent amber sheets in sterile peel pouches, indicated for infected or colonised chronic ulcers where sustained antiseptic activity is required.

Nanofiber Diameter Distribution Governs Exudate Handling in PVA Electrospun Dressings

Electrospinning of polyvinyl alcohol into nonwoven nanofiber mats produces a dressing architecture whose pore size, surface area, and fluid wicking capacity are directly determined by fibre diameter distribution, which in turn is governed by solution properties, process parameters, and environmental conditions. A partially hydrolysed PVA grade with intermediate alcoholysis (e.g., PVA 217, DP ~1700, hydrolysis 87–89 mol%) is dissolved at 10–14 wt% in deionised water; the solution surface tension of approximately 45 mN/m and conductivity adjusted to 200–400 µS/cm by addition of sodium chloride (0.05–0.1 wt%) are critical for achieving stable Taylor cone formation and suppressing bead defects. The dope is loaded into a syringe pump and fed through a blunt-tipped needle of 0.8 mm inner diameter at a flow rate of 0.3–0.8 mL/h, while a high-voltage power supply applies 18–28 kV to the needle relative to a grounded rotating drum collector covered with aluminum foil and positioned at a distance of 12–18 cm. When the relative humidity in the spinning enclosure exceeds 50%, water absorption by the elongating jet causes fibre coalescence and produces ribbon-like morphologies that reduce effective porosity and capillary wicking—an effect quantified by a drop in vertical wicking height from 15 mm to 6 mm within 60 seconds as measured by the DIN 53924 strip test. Fibre diameter, analysed from scanning electron micrographs using image analysis software per ASTM D3776‑equivalent methodologies, typically ranges from 200 nm to 600 nm; a tighter distribution centred around 300–400 nm yields optimal balance between liquid uptake (800–1200 g/m²/24h MVTR) and mechanical integrity (tensile strength 4–8 MPa at 25% elongation). The as-spun mat is thermally crosslinked by exposure to glutaraldehyde vapour at 60 °C for 2 hours or by microwave-assisted heating to 80 °C for 15 minutes to render it insoluble, then rinsed and vacuum-dried. Compliance with ISO 10993-6 local tissue reaction and EN 13726-3 wound dressing comfort testing is required; for exudate management, free swell absorptive capacity must exceed 200% and fluid handling capacity (EN 13726-2) should accommodate 0.3–0.5 mL/cm² over 24 hours. The electrospun PVA dressing is presented as a flexible, breathable sheet that contours to irregular wound surfaces and is designed for moderately exuding partial-thickness burns and abrasions.Injectable self-healing wound fillers based on dynamic boronate ester crosslinks exploit the cis-diol structure of PVA to achieve shear-thinning behaviour suitable for delivery through narrow-gauge cannulas into irregular wound cavities, where the material rapidly resolidifies into a cohesive hydrogel. A fully hydrolysed PVA (grade 1799) is formulated as a 4–6 wt% aqueous solution and sterilised by autoclaving at 121 °C for 20 minutes; a separate crosslinker solution of borax (sodium tetraborate decahydrate) at 0.5–1.0 wt% is similarly prepared and sterilised. The two components are mixed in a dual-barrel syringe fitted with a static mixer tip just before application, at a volumetric ratio optimised to yield a final PVA concentration of 3–5% and borax concentration of 0.3–0.6%, which produces a gel with a storage modulus (G′) of 200–800 Pa and loss modulus (G″) between 50 and 150 Pa at 1 Hz as determined by oscillatory rheology using a parallel-plate geometry. The dynamic nature of the boronate-diol linkages allows rapid self-repair after injection-induced network disruption, with recovery of ≥85% of the initial G′ within 60 seconds at 37 °C; this is critical for maintaining wound coverage during patient movement. The gel formulation adheres moderately to moist tissue but must be applied over a clean, debrided wound bed, as necrotic tissue and high protein exudate can competitively bind borate ions and decrease crosslink density, causing a gradual viscosity reduction and potential drainage from the wound. Biocompatibility evaluation encompasses ISO 10993-4 haemolysis testing (<2% haemolytic index), ISO 10993-11 acute systemic toxicity, and ISO 10993-6 intramuscular implantation to assess degradation and local tissue response, with the expectation that the PVA-borate complex gradually disintegrates and is absorbed or washed away with exudate over 3–7 days without requiring sharp debridement. The product is presented as a kit with pre-filled syringes and is indicated for managing deep, tunnelling wounds and surgical defects where conformal contact is essential.

Core Medical Device Standards Applicable to PVA Wound Dressing Products

Standard	Title / Test Focus	Typical Acceptance Criterion for PVA-Based Dressings
ISO 10993-5	Biological evaluation – In vitro cytotoxicity	Cell viability ≥ 70% by MTT assay on L929 fibroblasts
ISO 10993-10	Tests for skin sensitisation, irritation, and intracutaneous reactivity	Primary irritation index < 0.4; no erythema/oedema grade > 1
EN 13726-1	Test methods for primary wound dressings – Aspects of absorbency and MVTR	Free swell absorptive capacity ≥ 150%; MVTR range defined per product claim
EN 13726-3	Wearability and comfort – Water vapour permeability in contact with skin	Break force ≥ 5 N/25 mm for hydrated films
ASTM F2100-11	Standard specification for performance of materials used in medical face masks (fluid resistance, bacterial filtration applicable to dressings)	Synthetic blood penetration at 160 mmHg (≥ 120 mmHg for Level 2)
ISO 11137-1	Sterilisation of health care products – Radiation	Sterility assurance level 10⁻⁶; dose established per bioburden
ISO 13485	Quality management systems for medical devices	Process validation for all critical manufacturing steps
USP <87>	Biological reactivity tests, in vitro (Cytotoxicity)	Grade ≤ 2 (mild reactivity) under agarose overlay